Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Aiwu Ruth He, MD
- Target Recruit Count
- 6
- Registration Number
- NCT04541173
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 461
- Registration Number
- NCT04540211
- Locations
- 🇭🇰
Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin, Hong Kong
🇹🇭Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand
🇨🇳Affiliated Hospital of Chengde Medical University, Chengde City, China
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
- Conditions
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 518
- Registration Number
- NCT04524871
- Locations
- 🇺🇸
UC Irvine Medical Center, Orange, California, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸UCLA Center for East; West Medicine, Santa Monica, California, United States
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 829
- Registration Number
- NCT04513925
- Locations
- 🇺🇸
Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States
🇺🇸Illinois Cancer Care, Peoria, Illinois, United States
🇺🇸New England Cancer Specialists, Brunswick, Maine, United States
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
- Conditions
- Interventions
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Fundación GECP
- Target Recruit Count
- 4
- Registration Number
- NCT04512430
- Locations
- 🇪🇸
ICO Badalona, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital Universitario Insular de Gran canaria, Las Palmas De Gran Canaria, Gran Canaria, Spain
🇪🇸Complejo Hospitalario de Navarra, Pamplona, Iruña, Spain
Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- University Health Network, Toronto
- Registration Number
- NCT04510584
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
- Conditions
- Interventions
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 152
- Registration Number
- NCT04487067
- Locations
- 🇮🇹
Arcispedale Santa Maria Nuova; Oncologia, Reggio Emilia, Emilia-Romagna, Italy
🇮🇹Istituto Nazionale Dei Tumori; Dipartimento Chirurgia Generale - Unita' Trapianti Fegato, Milano, Lombardia, Italy
🇮🇹Azienda Ospedaliera Di Rilievo Nazionale E Di Alta Specializzazione Garibaldi, Palermo, Sicilia, Italy
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
- Conditions
- Interventions
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 68
- Registration Number
- NCT04480372
- Locations
- 🇨🇭
HFR Fribourg, Fribourg, Villars-sur-Glâne, Switzerland
🇨🇭St. Claraspital, Basel, Switzerland
🇨🇭Kantonsspital St. Gallen, St. Gallen, Switzerland
Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 18
- Registration Number
- NCT04477759
- Locations
- 🇺🇸
Froedtert & Medical College of Wisconsin, Milwaukee, Wisconsin, United States
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
- Conditions
- Interventions
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2024-10-15
- Target Recruit Count
- 232
- Registration Number
- NCT04471727
- Locations
- 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Cedar-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.